Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.64 |
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | RAB9A | P51151 | 4/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4208672 | 0.87 | RAB9A (0.68) | MEN1KMT2AHPGDMAPTRAB9A | |
| SCHEMBL13229811 | 0.85 | ALDH1A1 (0.50) | MEN1KMT2AHPGDMAPTRAB9A | |
| SCHEMBL2941168 | 0.81 | ALDH1A1 (0.57) | MEN1KMT2AHPGDMAPTRAB9A | |
| SCHEMBL10914085 | 0.81 | MEN1 (0.77) | MEN1KMT2AHPGDMAPTRAB9A | |
| SCHEMBL5008292 | 0.81 | MEN1 (0.77) | MEN1KMT2AHPGDMAPTRAB9A | |
| SCHEMBL28029676 | 0.80 | MEN1 (0.48) | MEN1KMT2AHPGDMAPTRAB9A | |
| SCHEMBL27967069 | 0.80 | ALDH1A1 (0.55) | HPGDMAPTRAB9ANPC1LMNA | |
| SCHEMBL1411294 | 0.78 | MEN1 (0.72) | MEN1KMT2AHPGDMAPTRAB9A | |
| SCHEMBL8661871 | 0.77 | MEN1 (0.82) | MEN1KMT2AHPGDMAPTRAB9A | |
| SCHEMBL2351707 | 0.77 | RAB9A (0.70) | MEN1KMT2AHPGDMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210864-A1 | PROCESS FOR THE PREPARATION OF N-ARYLMORPHOLINONES | DORSCH DIETER | 2010-08-19 | — | — | US | disclosed |
| US-7687624-B2 | Process for the production of N-arylmorpholinones | MERCK PATENT GMBH (DE) | 2010-03-30 | — | — | US | disclosed |
| US-20060217550-A1 | One pot process; cyclization; 4-(4-nitrophenyl)-3-oxomorpholine; Factor Xa inhibitors; , myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty and claudicatio intermittens | MERCK PATENT GMBH (DE) | 2006-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210864-A1 | PROCESS FOR THE PREPARATION OF N-ARYLMORPHOLINONES | CYP1A1, CYP1B1, OPRM1 | MEN1 2342/4885KMT2A 3641/4885HPGD 271/4885 |
| US-20060217550-A1 | One pot process; cyclization; 4-(4-nitrophenyl)-3-oxomorpholine; Factor Xa inhibitors; , myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty and claudicatio intermittens | PLAT, PCSK9, SERPINE1 | MEN1 1252/4885KMT2A 3928/4885HPGD 1290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.